SCHEMBL22697222

SCHEMBL22697222

COC(=O)c1ccc(Oc2cc3c(cc2OCCOCCN)CCN[C@]3(C)CC(=O)Nc2nccs2)cc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PCSK9 Q8NBP7 4/20 0.51
MAP1LC3B Q9GZQ8 4/20 0.51
ALDH1A1 P00352 2/20 0.34
BRAF P15056 1/20 0.34
LMNA P02545 3/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
PKM P14618 1/20 0.33
TP53 P04637 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ADRB2 P07550 1/20 0.33
SCN9A Q15858 1/20 0.32
KCNA5 P22460 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
MAPK1 P28482 1/20 0.32
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30228564 1.00 PCSK9 (0.51) PCSK9MAP1LC3BALDH1A1BRAFLMNA
SCHEMBL19995862 0.94 PCSK9 (0.50) PCSK9MAP1LC3BALDH1A1BRAFLMNA
SCHEMBL19995860 0.94 PCSK9 (0.50) PCSK9MAP1LC3BALDH1A1BRAFLMNA
SCHEMBL20001126 0.91 PCSK9 (0.50) PCSK9MAP1LC3BALDH1A1LMNANPC1
SCHEMBL30228844 0.91 PCSK9 (0.50) PCSK9MAP1LC3BALDH1A1LMNANPC1
SCHEMBL20001161 0.90 PCSK9 (0.48) PCSK9MAP1LC3BALDH1A1BRAFLMNA
SCHEMBL30228883 0.90 PCSK9 (0.48) PCSK9MAP1LC3BALDH1A1BRAFLMNA
SCHEMBL20001013 0.89 PCSK9 (0.45) PCSK9MAP1LC3BALDH1A1NPC1RAB9A
SCHEMBL30228570 0.89 PCSK9 (0.45) PCSK9MAP1LC3BALDH1A1NPC1RAB9A
SCHEMBL20000947 0.88 PCSK9 (0.46) PCSK9MAP1LC3BALDH1A1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11008313-B2 Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders MERCK SHARP & DOHME CORP. (US) 2021-05-18 US disclosed
US-20200369657-A1 SUBSTITUTED 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE MOLECULES AS PCSK9 ALLOSTERIC BINDERS MERCK SHARP & DOHME CORP. (US) 2020-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369657-A1 SUBSTITUTED 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE MOLECULES AS PCSK9 ALLOSTERIC BINDERS PCSK9, PCSK7, LDLR PCSK9 1/4885MAP1LC3B 2259/4885ALDH1A1 3833/4885
US-11008313-B2 Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders PCSK9, PCSK7, LDLR PCSK9 1/4885MAP1LC3B 2190/4885ALDH1A1 3915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.